Bevacizumab
- IVBevacizumabAvastin
Mechanism of Action
- A humanised monoclonal antibody directed against vascular endothelial growth factor (VEGF), whose expression is up-regulated during angiogenesis in certain cancers. Binding to VEGF reduces tumour bloodflow by promoting breakdown of tumour vasculature and inhibiting new blood vessel growth.
Clinical Use
- Indications
- Metastatic colorectal cancer
- Locally recurrent or metastatic breast cancer
- Advanced, metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC)
- Advanced or metastatic renal cancer
- Metastatic or unresectable melanoma
- Epithelial ovarian, fallopian tube or primary peritoneal cancer
- Recurrent or metastatic cervical cancer
- Grade IV glioma
- Adverse Effects
- Bone marrow suppression - leucopaenia, anaemia, thrombocytopaenia
- Peripheral neuropathy
- Arterial / venous thromboembolism
- Hypertension
- Proteinuria
- Nausea / vomiting / diarrhoea
- Fatigue